Case reportInconclusiveLimited evidenceTier 3 · early humann = 1
Journal of cancer research and therapeutics · Oct 2025 · case report
This case report describes a 17-year-old girl with a very rare ovarian rhabdomyosarcoma. The tumor was diagnosed by imaging, pathology, and immunohistochemistry, and it came back within 3 months after surgery. The authors report that she then received VAC chemotherapy (vincristine, actinomycin D, and cyclophosphamide), and they emphasize the need for earlier diagnosis and more standardized treatment approaches.
Studied with: vincristine, actinomycin D, cyclophosphamide.
Key findings
- Imaging showed a large solid-cystic pelvic mass.
- Histopathology and immunohistochemical markers (desmin, myogenin, WT1) confirmed ovarian rhabdomyosarcoma.
- Recurrence occurred within 3 months after surgical resection.
- VAC chemotherapy was given after early relapse.
Limitations: Single-patient case report.; No control group.; No quantitative treatment outcome data reported.; Cannot determine effectiveness of VAC from this report alone.; Focus is diagnostic and descriptive rather than evaluative..
Describes a rare ovarian cancer case and subsequent chemotherapy, but does not evaluate a compound's anticancer effect in a comparative way.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewInconclusiveLimited evidenceTier 4 · clinical
Current treatment options in oncology · Dec 2023 · narrative review
ovarian carcinosarcomaovarian cancer
This review summarizes what is known about ovarian carcinosarcoma, a rare and aggressive ovarian cancer. It discusses risk factors, prognostic markers, and current treatment approaches such as surgery followed by platinum-based chemotherapy, while noting that immunotherapy and HRD testing may be useful in some patients. The article does not report new experimental results from a trial or laboratory study.
Key findings
- Ovarian carcinosarcoma is described as rare and aggressive, with median overall survival under 2 years.
- Poor prognostic factors include advanced stage, older age, lymph node metastasis, suboptimal cytoreduction, heterologous histology, and increased VEGF, p53, and WT1 expression.
- Main treatment approach is cytoreductive surgery followed by platinum-based chemotherapy.
- Immunotherapy is described as promising, and HRD testing may help personalize therapy.
Limitations: Narrative review rather than original research.; No new patient cohort, control group, or quantitative treatment effect data reported in the abstract.; Most evidence discussed is from case reports and small studies.; The abstract does not specify which therapies or biomarkers were evaluated in detail..
Provides an overview of ovarian carcinosarcoma epidemiology, prognosis, and treatment options rather than testing a specific compound.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 536
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Mar 2022 · randomized phase III trial
This randomized phase III study compared paclitaxel plus carboplatin with paclitaxel plus ifosfamide in adults with uterine or ovarian carcinosarcoma. In uterine carcinosarcoma, paclitaxel plus carboplatin was not inferior to the ifosfamide regimen and had longer median overall survival and progression-free survival. Toxicities were broadly similar, although some side effects differed between the two groups.
Reported effects: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 · HR 0.87 [0.7–1.075], p P < .01 for noninferiority, P > .1 for superiority, n=449 · +4 more
Studied with: carboplatin, ifosfamide.
Key findings
- In uterine carcinosarcoma, paclitaxel plus carboplatin was not inferior to paclitaxel plus ifosfamide for overall survival.
- Median overall survival was 37 versus 29 months in uterine carcinosarcoma.
- Median progression-free survival was 16 versus 12 months in uterine carcinosarcoma.
- Toxicities were similar overall, with more hematologic toxicity in the paclitaxel-carboplatin arm and more confusion and genitourinary hemorrhage in the paclitaxel-ifosfamide arm.
- In ovarian carcinosarcoma, paclitaxel plus carboplatin had numerically longer survival outcomes, but the differences were not statistically significant.
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..
This study evaluates chemotherapy regimens in carcinosarcoma, a cancer setting, with direct survival and toxicity outcomes.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportTrialReported positiveLimited evidenceTier 3 · early humann = 2
Pediatric surgery international · May 2008 · case reports
This report describes two children with very rare primary ovarian rhabdomyosarcoma. After complete surgical removal, both received chemotherapy with vincristine, doxorubicin, and cyclophosphamide and had a good response. Both patients were alive 8 and 9 months after surgery.
Key findings
- Two pediatric cases of primary ovarian rhabdomyosarcoma were described.
- Both patients underwent complete resection of the primary tumor.
- Both received vincristine, doxorubicin, and cyclophosphamide chemotherapy.
- The abstract reports a good response to therapy and survival at 8 and 9 months post-operatively.
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..
Describes management of a rare ovarian cancer in children, including chemotherapy, but does not isolate the effect of any single compound.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed